Robust pre-clinical data indicate that vaccination with anti-Nogo-A antibodies or passive immunisation against Nogo-A reduces clinical symptoms, demyelination, and axonal damage in MS [105]. This evidence concerns the gene RTN4 and myeloid sarcoma.